Press Release: Novartis PluvictoTM shows -2-

data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

About Novartis

Novartis is reimagining medicine to improve and extend people's lives. We deliver high-value medicines that alleviate society's greatest disease burdens through technology leadership in R&D and novel access approaches. In our quest to find new medicines, we consistently rank among the world's top companies investing in research and development. About 108,000 people of more than 140 nationalities work together to bring Novartis products to nearly 800 million people around the world. Find out more at https://www.novartis.com

Novartis is on Twitter. Sign up to follow @Novartis at https://twitter.com/novartisnews https://twitter.com/novartisnews

For Novartis multimedia content, please visit https://www.novartis.com/news/media-library https://www.novartis.com/news/media-library

For questions about the site or required registration, please contact media.relations@novartis.com

References

1. Novartis Data on File.

2. Nuhn P, De Bono JS, Fizazi K et al. Update on systemic prostate cancer

therapies: management of metastatic castration-resistant prostate cancer

in the era of precision oncology. Eur Urol. 2019;75(1):88--99.

3. Sartor O, J. de Bono KN, Chi K, et al. Lutetium-177--PSMA-617 for

Metastatic Castration-Resistant Prostate Cancer. NEJM 2021; doi:

10.1056/NEJMoa2107322.

4. Kirby M, Hirst C, Crawford ED. Characterising the castration-resistant

prostate cancer population: a systematic review. Int J Clin Pract

2011;65(11):1180--92.

5. American Cancer Society. Survival Rates for Prostate Cancer. ACS website.

Available online:

https://www.cancer.org/cancer/prostate-cancer/detection-diagnosis-staging/survival-rates.html.

Last accessed October 2022.

6. de Bono J et al. Olaparib for Metastatic Castration-Resistant Prostate

Cancer. NEJM 2020; doi:10.1056/NEJMoa1911440.

7. de Wit R, de Bono J et al. Cabazitaxel versus Abiraterone or Enzalutamide

in Metastatic Prostate Cancer. NEJM 2019; doi: 10.1056/NEJMoa1911206.

8. Komura K et al. Comparison of Radiographic Progression-Free Survival and

PSA Response on Sequential Treatment Using Abiraterone and Enzalutamide

for Newly Diagnosed Castration-Resistant Prostate Cancer: A Propensity

Score Matched Analysis from Multicenter Cohort. Journal of clinical

medicine 2019; doi:10.3390/jcm8081251.

9. Tannock, I et al. Docetaxel plus prednisone or mitoxantrone plus

prednisone for advanced prostate cancer. NEJM 2004;

doi:10.1056/NEJMoa040720.

10. Pluvicto [prescribing information]. Millburn, NJ: Advanced Accelerator

Applications USA, Inc.; 2022.

11. Advanced Accelerator Applications USA, Inc. PLUVICTO(TM) Canadian Product

Monograph. August 25, 2022.

12. Pluvicto [Summary of Product Characteristics]. Great Britain. 2022.

13. Novartis Pharmaceuticals. 177Lu-PSMA-617 vs. Androgen Receptor-directed

Therapy in the Treatment of Progressive Metastatic Castrate Resistant

Prostate Cancer (PSMAfore). U.S. National Library of Medicine: Clinical

Trials. 2020; NCT04689828.

14. Novartis. Press Release.

https://www.novartis.com/news/media-releases/novartis-receives-positive-chmp-opinion-pluvicto-patients-progressive-psma-positive-metastatic-castration-resistant-prostate-cancer.

Last accessed October 2022.

15. Novartis Pharmaceuticals. An International Prospective Open-label,

Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With

Soc, Versus SoC Alone, in Adult Male Patients With mHSPC (PSMAddition).

U.S. National Library of Medicine: Clinical Trials. 2021; NCT04720157.

16. Sung H, Ferlay J, Siegel RL, Sung H, et al. Global cancer statistics

2020: GLOBOCAN estimates of incidence and mortality worldwide for 36

cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209-249.

doi:10.3322/caac.21660.

17. Jadvar H. Targeted radionuclide therapy: an evolution toward precision

cancer treatment. AJR Am J Roentagenol. 2017;209(2);277-288.

18. Jurcic JG, Wong JYC, Knoc SJ, et al. Targeted radionuclide therapy. In:

Tepper JE, Foote RE, Michalski JM, eds. Gunderson & Tepper's Clinical

Radiation Oncology. 5th ed. Elsevier, Inc. 2021;71(3):209-249.

19. Hope TA, Aggarwal R, Chee B, et al. Impact of 68Ga-PSMA-11 PET on

management in patients with biochemically recurrent prostate cancer. J

Nucl Med 2017;58(12):1956--61.

20. Hupe MC, Philippi C, Roth D, et al. Expression of prostate-specific

membrane antigen (PSMA) on biopsies is an independent risk stratifier of

prostate cancer patients at time of initial diagnosis. Front Oncol

2018;8:623.

21. Bostwick DG, Pacelli A, Blute M, et al. Prostate specific membrane

antigen expression in prostatic intraepithelial neoplasia and

adenocarcinoma: a study of 184 cases. Cancer 1998;82(11):2256--61.

22. Pomykala KL, Czernin J, Grogan TR, et al. Total-body 68Ga-PSMA-11 PET/CT

for bone metastasis detection in prostate cancer patients: potential

impact on bone scan guidelines. J Nucl Med 2020;61(3):405--11.

23. Minner S, Wittmer C, Graefen M, et al. High level PSMA expression is

associated with early PSA recurrence in surgically treated prostate

cancer. Prostate 2011;71(3):281--8.

24. Hofman MS, Violet J, Hicks RJ et al. [177Lu]-PSMA-617 radionuclide

treatment in patients with metastatic castration-resistant prostate

cancer (LuPSMA trial): a single-centre, single-arm, phase 2.

25. Sant GR, Knopf KB, Albala DM. Live-single-cell phenotypic cancer

biomarkers-future role in precision oncology? NPJ Precision Oncology

2017;1(1):21.

# # #

Novartis Media Relations

E-mail: media.relations@novartis.com

Central North America

Richard Jarvis +41 79 584 2326 Julie Masow +1 862 579 8456

Anja von Treskow +41 79 392 9697 Michael Meo +1 862 274 5414

Anna Schäfers +41 79 801 7267 Mary Carmichael +1 862 200 8344

Switzerland

Satoshi Sugimoto +41 79 619 2035

Novartis Investor Relations

Central investor relations line: +41 61 324 7944

E-mail: investor.relations@novartis.com

Central North America

Samir Shah +41 61 324 7944 Sloan Simpson +1 862 345 4440

Nicole Zinsli-Somm +41 61 324 3809 Parag Mahanti +1 973 876 4912

Isabella Zinck +41 61 324 7188

(END) Dow Jones Newswires

December 05, 2022 01:15 ET (06:15 GMT)